Eyconis Announces First Patients Dosed In Phase 1b/2a OVERTURE Trial Of EYC-0305 In Treatment-Naïve Wet AMD Patients, Using TransCon Technology Licensed From Ascendis Pharma

Loading news article.

Eyconis Announces First Patients Dosed In Phase 1b/2a OVERTURE Trial Of EYC-0305 In Treatment-Naïve Wet AMD Patients, Using TransCon Technology Licensed From Ascendis Pharma | WAPE

Eyconis Announces First Patients Dosed In Phase 1b/2a OVERTURE Trial Of EYC-0305 In Treatment-Naïve Wet AMD Patients, Using TransCon Technology Licensed From Ascendis Pharma

Article summary

Related companies

Comments —